SOPHiA GENETICS and AstraZeneca have announced a significant expansion of their partnership, launching a multi-year collaboration that will harness artificial intelligence to improve breast cancer treatment outcomes. The partnership, announced on August 5, 2025, will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer.
AI-Powered Predictive Modeling for Breast Cancer
The collaboration centers on SOPHiA GENETICS's AI Factories, which are derived from cutting-edge computing protocols and trained on one of the most diverse multimodal datasets in healthcare. These AI systems offer powerful predictive insights for assessing patient prognosis and treatment response. AstraZeneca will utilize these AI Factories to analyze multimodal healthcare data, including genomics, imaging, and clinical data, to generate AI-powered insights aimed at optimizing breast cancer outcomes.
The partnership also supports the potential development of a bespoke AI-powered predictive model specifically designed to optimize outcomes for individuals undergoing breast cancer treatment. This represents a significant step toward personalized medicine in oncology care.
Real-World Evidence Generation Across Two Continents
A key component of the expanded collaboration involves real-world evidence generation in Europe and North America. The companies will work together to uncover key drivers of treatment efficacy, address critical knowledge gaps, and enhance clinical decision-making through deeper insights derived from comprehensive data analysis.
"We are proud to deepen our partnership with AstraZeneca through this significant new initiative, which highlights the growing demand for secure, compliant, and scalable real-world AI applications," said Ross Muken, President of SOPHiA GENETICS. "Our platform is purpose-built to manage complex healthcare data environments, and this collaboration reinforces our shared commitment to driving better patient outcomes through trusted, federated analytics powered by data and AI."
Strategic AI Integration in Oncology Development
For AstraZeneca, this collaboration aligns with their broader AI strategy in oncology clinical development. Jorge Reis-Filho, Chief AI and Data Scientist at AstraZeneca, emphasized the importance of multimodal data integration: "At AstraZeneca, a core component of our AI strategy has been rooted in the deployment of frontier AI solutions across oncology clinical development. Fine tuning and augmenting our models with multimodal data – including our own data and the data that will be generated as part of this collaboration – is helping us to generate a more holistic understanding of disease biology and biomarkers to tailor the most effective treatment to patients living with cancer."
Technology Platform and Capabilities
SOPHiA GENETICS operates as a cloud-native healthcare technology company and global leader in data-driven medicine. The company's SOPHiA DDM™ Platform analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. The platform is designed to manage complex healthcare data environments while maintaining security, compliance, and scalability standards.
This collaboration reinforces SOPHiA GENETICS' position as a trusted technology partner in the pharmaceutical industry and underlines its commitment to advancing global health through federated data analytics and artificial intelligence. The partnership represents a significant investment in AI-driven approaches to cancer care, with the potential to transform how breast cancer treatments are selected and optimized for individual patients.
